Lake Street raised the firm’s price target on Castle Biosciences to $34 from $32 and keeps a Buy rating on the shares after the company reported Q1 adjusted revenues “well ahead” of the firm’s estimate and consensus. The company raised guidance to $255M-$265M to reflect outperformance in Q1 and incremental Dx-SCC contribution, notes the firm, which raised its own 2024 revenue estimate and continue to see the company’s strategy of advancing its dermatology franchise while judiciously investing in its newer verticals generating value for investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences Unveils Informative Management Presentation Slides
- Baird says FDA final LDT rule favorable for Life Sciences, Diagnostics coverage
- Castle Biosciences Secures Loan and Reshuffles Board
- Castle Biosciences management to meet virtually with Stephens
- Castle’s DecisionDx-SCC study shows predictive accurracy with patients
